JLS Fund, a notable player in the fields of science, technology, and neurology, is actively exploring the restorative potential of plant-based and psychedelic treatments.
This innovative fund is committed to enhancing healthcare by focusing its efforts towards the creation of effective treatments for enduring mental and physical conditions.
Moreover, the fund is passionate about technological breakthroughs that could potentially expedite and improve the delivery of these novel treatments. Such initiatives have earned recognition at the forthcoming Transformative Impact Summit NYC, a conference designed to unite thought-leaders to drive transformative change.
Psilera and JLS Fund: Driving Progress in Neurological Treatments
Psilera, another significant player in the industry, mirrors this commitment to innovation and is making commendable progress in neurological treatments. The company is revolutionizing the utilization of psychoactive natural substances for the development of future-generation treatments.
This shared dedication to healthcare revolution is supported by a proficient team at JLS Fund, led by managing partners Lindsay Hoover, Simeon Schnapper, and Michael Gruber, with investor relations and partnerships managed by Jeffrey Siegel. Their expertise is supplemented by a skilled team of advisors including Mark Losh, Walter Greenleaf, and David Hirsch, who possess a diverse skill set in technology, psychology, and policy.
Simeon Schnapper: Raising the Bar on Psychedelic Investments
Simeon Schnapper, a managing partner at JLS Fund, will be sharing his unique insights on psychedelic investments at the renowned Transformative Impact Summit NYC. The summit serves as a platform where influential innovators, funders and policy-makers can foster collaboration to spark meaningful change.
Schnapper’s vision into the world of psychedelic investments has also been featured in various media interviews and articles recently. His influential commentary is crucial in the ongoing discussions regarding investment possibilities in the growing field of psychedelic treatments.
In the build-up to the summit, JLS Fund is aiming to maintain visibility in the psychedelic discussion, through strategic initiatives such as an interactive Fireside Chat featuring Simeon Schnapper and Leonard Pickard; dialogues led by Michael Gruber that delve into the future of medicine; and discussions with Lindsay Hoover focusing on investment opportunities.
Recognized as an influential venture capital entity assisting in the transition of psychedelics into medical treatments, JLS Fund is consistently setting waves in the industry. As the Microdose Virtual Psychedelic Conference draws near, the industry is looking forward to more insights from this team of experts, who are ready to push the boundaries in the mental health field, particularly at the intersection of psychedelics & technology. The JLS Fund is rapidly becoming a leader in psychedelic investments.
